Marchex heads into the post-earnings session with a Q1 miss on both revenue and earnings, but a $10 million strategic funding deal with Archenia adds a complicating wrinkle to what would otherwise be a clean bearish setup.
The headline numbers disappointed. Adjusted EPS came in at -$0.03 against a -$0.01 consensus estimate. Revenue landed at $10.62 million, short of the $10.89 million forecast. That continues a multi-quarter revenue compression story — Q4 2025 sales were $10.85 million, already down from $11.92 million a year prior. The full-year 2025 loss widened to $5.24 million from $4.95 million. The direction of travel on fundamentals has not changed.
What complicates that read is the Archenia transaction. Marchex announced a $10 million funding commitment from Archenia, which provides the company a meaningful liquidity cushion relative to its micro-cap profile. With the stock trading at $1.59 — down 7.3% on the week before earnings — and a market cap that makes every $10 million feel material, the deal carries outsized signalling value even if it introduces execution risk. Whether it changes the fundamental narrative is a question the earnings call transcript will clarify.
Short sellers have been quietly retreating into the print, which is worth noting as context. Short interest as a percentage of the free float is a marginal 0.046% — far too small to constitute a meaningful directional signal. What is notable is the trajectory: short interest fell nearly 27% over the past month, dropping from roughly 26,000 shares to under 18,000. That unwinding accelerated this week, with an additional 9.7% decline. The lending market is extraordinarily loose, with availability in the thousands of percent and cost to borrow running at 21.4% — elevated for a stock with this little short interest, suggesting the borrowing cost is structural rather than a sign of squeeze dynamics. Options positioning is overwhelmingly call-sided: the put/call ratio sits at 0.017, well below its already-low 20-day average of 0.023.
Ownership concentration is the defining structural feature of this name. Edenbrook Capital holds 33.5% of shares outstanding. Co-founder Russell Horowitz retains 12.9%. Together, those two positions alone account for nearly half the float-affecting supply, which mechanically inflates the cost to borrow and reduces the freely tradeable pool. The most recent insider-level activity was a cluster of equity awards to the President and COO in March — standard compensation grants with no cash value — and Edenbrook itself was a buyer at prices between $1.70 and $1.75 back in March 2025. CEO Edwin Miller also accumulated shares in November 2024 at similar levels around $1.73.
Analyst coverage is effectively absent. The sole meaningful data point on the Street is a Roth Capital Buy with a $4.00 target, but that action was reported in December 2021 and should not be treated as a current view. No analyst has publicly updated a rating in over four years. The stock trades entirely on its own momentum and on the decisions of its concentrated holders.
The factor scores show one genuinely interesting data point: EPS surprise ranks at the 88th percentile across the universe — which makes today's miss all the more notable, as it breaks a pattern of beating expectations. The ORTEX short score is a mild 36.1, and it has barely moved over the past two weeks, signalling no escalation in bearish conviction despite the price weakness.
With Q1 results now in the public domain and the Archenia deal terms under scrutiny, the next thing to watch is whether the $10 million funding commitment converts from a target announcement into a closed transaction, and what management said on the earnings call about the cadence and conditions attached to that capital.
See the live data behind this article on ORTEX.
Open MCHX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
